Ownership and insider activity for Oragenics, Inc. (OGEN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option.
Price
| Price | $0.50 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.1M | $6.2M | $20.2M | $18.3M | $17.6M | $27.3M | $11.4M | $3.5M | $864840 | $4.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 | $6987 | 0 | 0 | 0 | $53082 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $4.2M | $7.2M | $21.9M | $18.8M | $18.0M | $27.7M | $14.3M | $3.9M | $1.5M | $10.1M |
| Property, Plant & Equipment | $87462 | $21659 | $116276 | $914652 | $697851 | $523590 | $468502 | $9811 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.3M | $7.2M | $22.0M | $19.8M | $18.7M | $28.2M | $14.8M | $5.0M | $1.5M | $10.1M |
| Accounts Payable | $461344 | $618360 | $828706 | $1.2M | $330379 | $854983 | $246690 | $1.2M | $1.1M | $1.6M |
| Short-term Debt | $66377 | $80478 | $124213 | $143864 | $228227 | $303416 | $267640 | $312703 | $328528 | $227348 |
| Total Current Liabilities | $1.3M | $898522 | $1.2M | $1.9M | $1.3M | $1.4M | $1.6M | $1.8M | $1.7M | $1.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.3M | $898522 | $1.2M | $2.5M | $1.8M | $1.7M | $1.7M | $1.8M | $1.7M | $1.8M |
| Retained Earnings | -$94.7M | -$101.4M | -$111.4M | -$127.4M | -$154.4M | -$171.3M | -$185.6M | -$206.2M | -$216.8M | -$226.6M |
| Total Equity | $3.0M | $6.3M | $20.9M | $17.2M | $16.8M | $26.5M | $13.0M | $3.2M | -$211885 | $8.3M |
| Total Debt | $66377 | $80478 | $124213 | $979650 | $898917 | $797206 | $624526 | $322514 | $328528 | $227348 |
| Net Debt | -$4.0M | -$6.1M | -$20.1M | -$17.3M | -$16.7M | -$26.5M | -$10.8M | -$3.2M | -$536312 | -$8.2M |
| Working Capital | $2.9M | $6.3M | $20.8M | $17.0M | $16.6M | $26.3M | $12.7M | $2.1M | -$211885 | $8.3M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.01 |
Profitability
| Return on Equity | -144.23% |
| Return on Invested Capital | -279.54% |
| Return on Assets | -183.59% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AIM · CANF · CNSP · ENSC · KALA · KZIA · QLGN
Explore sector: Healthcare · Biotechnology
More sections of OGEN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks